Publication: Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?
No Thumbnail Available
Date
2012-01-01T00:00:00Z
Authors
Authors
Demirkol, Demet
Yildizdas, Dincer
BAYRAKCİ, BENAN
KARAPINAR, BÜLENT
Kendirli, Tanil
KÖROĞLU, TOLGA FİKRİ
DURSUN, OĞUZ
Erkek, Nilgun
Gedik, Hakan
Citak, Agop
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
Introduction: Hyperferritinemia is associated with increased mortality in pediatric sepsis, multiple organ dysfunction syndrome (MODS), and critical illness. The International Histiocyte Society has recommended that children with hyperferritinemia and secondary hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) should be treated with the same immunosuppressant/cytotoxic therapies used to treat primary HLH. We hypothesized that patients with hyperferritinemia associated secondary HLH/sepsis/MODS/MAS can be successfully treated with a less immunosuppressant approach than is recommended for primary HLH.
Description
Keywords
Hyperferritinemia
Citation
Demirkol D., Yildizdas D., BAYRAKCİ B., KARAPINAR B., Kendirli T., KÖROĞLU T. F. , DURSUN O., Erkek N., Gedik H., Citak A., et al., -Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?-, CRITICAL CARE, cilt.16, 2012